Ultragenyx Pharmaceutical (RARE)
(Delayed Data from NSDQ)
$43.85 USD
-0.43 (-0.97%)
Updated Apr 25, 2024 04:00 PM ET
3-Hold of 5 3
F Value C Growth F Momentum F VGM
Price, Consensus and EPS Surprise
RARE 43.85 -0.43(-0.97%)
Will RARE be a Portfolio Killer in April?
Zacks Investment Research is releasing its prediction for RARE based on the 1-3 month trading system that more than doubles the S&P 500.
About Price, Consensus and EPS Surprise
The Price, Consensus and EPS Surprise chart displays the company's stock price along with the consensus estimate and the EPS surprise. Zacks tracks individual sell-side analyst estimates and creates a consensus EPS estimates. The consensus estimate is the average of all the current estimates made available by brokerage analysts. Consensus estimates are more advantageous because they reduce the risk of any single analyst making an incorrect forecast. ZACKS CONSENSUS ESTIMATE = THE AVERAGE OF ALL CURRENT EPS ESTIMATES. EPS Surprise is the difference (expressed as a percentage) between the actual reported quarterly earnings per share (EPS) vs the estimated quarterly EPS. A company that reports $1.10 in actual quarterly EPS vs. $1.00 in estimated quarterly EPS would show a 10% positive EPS surprise. ((Actual EPS - Estimated EPS) / absolute Estimated EPS) *100 = EPS Surprise %.
Zacks News for RARE
Ultragenyx (RARE) Meets Efficacy Goal in Neuro Disease Study
Is First Trust NYSE Arca Biotechnology ETF (FBT) a Strong ETF Right Now?
RARE: What are Zacks experts saying now?
Zacks Private Portfolio Services
Should You Invest in the First Trust NYSE Arca Biotechnology ETF (FBT)?
Ultragenyx (RARE) Q4 Loss Narrower Than Expected, Revenues Beat
Compared to Estimates, Ultragenyx (RARE) Q4 Earnings: A Look at Key Metrics
Other News for RARE
Ultragenyx to Host Conference Call for First Quarter 2024 Financial Results and Corporate Update
Ultragenyx price target raised by $2 at TD Cowen, here's why
Analysts Offer Insights on Healthcare Companies: Neurocrine (NBIX) and Ultragenyx Pharmaceutical (RARE)
First Week of RARE June 21st Options Trading
Wall Street Analysts Are Bullish on Top Healthcare Picks